Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1163
Abstract: Brepocitinib is a tyrosine kinase 2 and Janus kinase 1 inhibitor in development for treatment of inflammatory autoimmune diseases. This analysis aimed to add to the pharmacokinetic knowledge of the medication, through development of a… read more here.
Keywords: volunteers patients; healthy volunteers; brepocitinib; model ... See more keywords
Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations
Sign Up to like & getrecommendations! Published in 2024 at "Pharmaceutical Research"
DOI: 10.1007/s11095-024-03654-w
Abstract: Topical brepocitinib, a tyrosine kinase (TYK)2/Janus kinase (JAK)1 inhibitor, is in development for psoriasis (PsO) and atopic dermatitis (AD). Quantitative analyses of prior clinical trial data were used to inform future clinical trial designs. Two… read more here.
Keywords: clinical trial; brepocitinib; brepocitinib topical; atopic dermatitis ... See more keywords
A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a 14 C-microdose approach.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15786
Abstract: AIMS Brepocitinib is a tyrosine kinase 2/Janus kinase 1 inhibitor being investigated for the treatment of several autoimmune diseases. This study assessed the absorption, distribution, metabolism and excretion of oral brepocitinib, and the absolute oral… read more here.
Keywords: period; brepocitinib; dose; absorption distribution ... See more keywords
How will brepocitinib cream compare with established treatments for mild‐to‐moderate eczema?
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21880
Abstract: Brepocitinib (PF-06700841) is a small-molecule dual inhibitor of tyrosine kinase 2 and Janus kinase (JAK)1 previously administered orally in trials of other inflammatory dermatoses. In this issue of the BJD, Landis and coauthors report the… read more here.
Keywords: mild moderate; brepocitinib; brepocitinib cream; moderate eczema ... See more keywords
Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.17909
Abstract: The phase 2a ALLEGRO trial (NCT02974868) investigated the safety and efficacy of ritlecitinib (PF‐06651600) and brepocitinib (PF‐06700841) in adults with alopecia areata. No randomized controlled trial for alopecia areata has evaluated correlations between clinician‐assessed hair… read more here.
Keywords: reported outcomes; brepocitinib; patient reported; trial ... See more keywords
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite
Sign Up to like & getrecommendations! Published in 2024 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.124.001750
Abstract: Brepocitinib is an oral once-daily Janus kinase 1 and Tyrosine kinase 2 selective inhibitor currently in development for the treatment of several autoimmune disorders. Mass balance and metabolic profiles were determined using accelerator mass spectrometry… read more here.
Keywords: dose; brepocitinib; metabolism; formation ... See more keywords